

Maria Ilaria Del Principe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4290780/publications.pdf>

Version: 2024-02-01

62
papers

3,078
citations

186209

28
h-index

161767

54
g-index

63
all docs

63
docs citations

63
times ranked

3646
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131. | 0.6 | 309 |
| 2 | Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-341. | 0.6 | 246 |
| 3 | Clinical significance of CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2001, 98, 2633-2639. | 0.6 | 242 |
| 4 | Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873. | 0.6 | 226 |
| 5 | COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168. | 6.9 | 189 |
| 6 | Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861. | 0.6 | 171 |
| 7 | Toward Optimization of Postremission Therapy for Residual Disease—Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951. | 0.8 | 165 |
| 8 | Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303. | 0.6 | 126 |
| 9 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506. | 1.2 | 106 |
| 10 | Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29. | 2.8 | 98 |
| 11 | Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128. | 2.0 | 86 |
| 12 | Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. <i>Haematologica</i> , 2007, 92, 605-611. | 1.7 | 76 |
| 13 | Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998. | 0.6 | 62 |
| 14 | Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85. | 1.7 | 53 |
| 15 | CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014075. | 0.5 | 50 |
| 16 | A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363. | 2.0 | 49 |
| 17 | The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752. | 2.0 | 45 |
| 18 | Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628. | 3.2 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A cluster of <i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>) infection in haematological patients: a first Italian report and review of literature. <i>Mycoses</i> , 2016, 59, 594-601. | 1.8 | 44 |
| 20 | Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. <i>American Journal of Hematology</i> , 2020, 95, 1466-1472. | 2.0 | 42 |
| 21 | Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. <i>Thrombosis Research</i> , 2013, 132, 511-514. | 0.8 | 41 |
| 22 | Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214. | 1.8 | 39 |
| 23 | ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292. | 0.7 | 38 |
| 24 | Thrombosis in adult patients with acute leukemia. <i>Current Opinion in Oncology</i> , 2017, 29, 448-454. | 1.1 | 38 |
| 25 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774. | 0.8 | 34 |
| 26 | P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 121, 730-738. | 1.2 | 32 |
| 27 | A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631. | 2.0 | 32 |
| 28 | Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123. | 2.0 | 30 |
| 29 | High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1509-1513. | 0.8 | 30 |
| 30 | CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212. | 1.2 | 26 |
| 31 | Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097. | 2.0 | 25 |
| 32 | Monitoring of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 582-588. | 1.1 | 24 |
| 33 | Apoptosis and immaturity in acute myeloid leukemia. <i>Hematology</i> , 2005, 10, 25-34. | 0.7 | 19 |
| 34 | Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23. | 1.8 | 19 |
| 35 | Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106. | 0.6 | 16 |
| 36 | The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 383-387. | 1.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. <i>Haematologica</i> , 2022, 107, 996-999. | 1.7 | 15 |
| 38 | Clinical significance of c.7544â€“7545 del<sc>CT </sc><i><sc>NOTCH</sc>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418. | 1.2 | 14 |
| 39 | Applications and efficiency of flow cytometry for leukemia diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1089-1097. | 1.5 | 14 |
| 40 | Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. <i>Haematologica</i> , 2020, 106, 39-45. | 1.7 | 14 |
| 41 | <sc>ESCCA</sc>/<sc>ISCCA</sc> protocol for the analysis of cerebrospinal fluid by multiparametric flowâ€“cytometry in hematological malignancies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 269-281. | 0.7 | 13 |
| 42 | Minimal residual disease as biomarker for optimal biologic dosing of <sc>ARA</sc>â€“<sc>C</sc> in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131. | 2.0 | 12 |
| 43 | Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 445-450. | 0.6 | 11 |
| 44 | â€“Real-lifeâ€“™ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068. | 1.3 | 11 |
| 45 | Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52. | 0.8 | 10 |
| 46 | Extensive toxic epidermal necrolysis following brentuximab vedotin administration. <i>Annals of Hematology</i> , 2015, 94, 355-356. | 0.8 | 9 |
| 47 | Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6246. | 1.7 | 9 |
| 48 | Evaluation of the prognostic relevance of <sc>L</sc>â€“selectin and ICAM1 expression in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2008, 80, 107-114. | 1.1 | 7 |
| 49 | Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, e189-e191. | 0.8 | 7 |
| 50 | Longitudinal detection of <i>DNMT3A</i>^{R882H} transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123. | 2.0 | 7 |
| 51 | Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEMâ€“12B study). <i>Mycoses</i> , 2020, 63, 1094-1100. | 1.8 | 6 |
| 52 | High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel)</i> , 2021, 6, 1065. | 1.0 | 6 |
| 53 | Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2006, 85, 136-138. | 0.8 | 5 |
| 54 | An evaluation of enasidenib for the treatment of acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1935-1942. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1787-1800. | 1.1 | 4 |
| 56 | Advances in the treatment of elderly and frail patients with acute myeloid leukemia. Current Opinion in Oncology, 2014, 26, 663-669. | 1.1 | 4 |
| 57 | Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016 survey. Mycoses, 2022, 65, 171-177. | 1.8 | 3 |
| 58 | Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 857-858. | 0.6 | 2 |
| 59 | Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms. Leukemia and Lymphoma, 2022, 63, 1754-1757. | 0.6 | 2 |
| 60 | In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. Journal of Clinical Medicine, 2022, 11, 1776. | 1.0 | 1 |
| 61 | Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. Annals of Hematology, 2014, 93, 1611-1612. | 0.8 | 0 |
| 62 | When Viruses Meet Fungi: Tackling the Enemies in Hematology. Journal of Fungi (Basel, Switzerland), 2022, 8, 184. | 1.5 | 0 |